Cargando…

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xu, Li, Huiping, Coussy, Florence, Callens, Celine, Lerebours, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736652/
https://www.ncbi.nlm.nih.gov/pubmed/31564802
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03
_version_ 1783450546269585408
author Liang, Xu
Li, Huiping
Coussy, Florence
Callens, Celine
Lerebours, Florence
author_facet Liang, Xu
Li, Huiping
Coussy, Florence
Callens, Celine
Lerebours, Florence
author_sort Liang, Xu
collection PubMed
description As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall survival (OS) benefit and serious adverse effects. Missing targeted population urged us to identify the predictive biomarkers for BEV efficacy. In this review we focus on the research in breast cancer and provide recent investigations on clinical, radiological, molecular and gene profiling markers of BEV efficacy, including the new results from randomized phase III clinical trials evaluating the efficacy of BEV in combination with comprehensive biomarker analyses. Current evidences indicate some predictive values for genetic variants, molecular imaging, VEGF pathway factors or associated factors in peripheral blood and gene profiling. The current challenge is to validate those potential biomarkers and implement them into clinical practice.
format Online
Article
Text
id pubmed-6736652
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-67366522019-09-27 An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress? Liang, Xu Li, Huiping Coussy, Florence Callens, Celine Lerebours, Florence Chin J Cancer Res Review Article As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall survival (OS) benefit and serious adverse effects. Missing targeted population urged us to identify the predictive biomarkers for BEV efficacy. In this review we focus on the research in breast cancer and provide recent investigations on clinical, radiological, molecular and gene profiling markers of BEV efficacy, including the new results from randomized phase III clinical trials evaluating the efficacy of BEV in combination with comprehensive biomarker analyses. Current evidences indicate some predictive values for genetic variants, molecular imaging, VEGF pathway factors or associated factors in peripheral blood and gene profiling. The current challenge is to validate those potential biomarkers and implement them into clinical practice. AME Publishing Company 2019-08 /pmc/articles/PMC6736652/ /pubmed/31564802 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03 Text en Copyright © 2019 Chinese Journal of Cancer Research. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review Article
Liang, Xu
Li, Huiping
Coussy, Florence
Callens, Celine
Lerebours, Florence
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title_full An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title_fullStr An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title_full_unstemmed An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title_short An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
title_sort update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: do we make progress?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736652/
https://www.ncbi.nlm.nih.gov/pubmed/31564802
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03
work_keys_str_mv AT liangxu anupdateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT lihuiping anupdateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT coussyflorence anupdateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT callensceline anupdateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT lereboursflorence anupdateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT liangxu updateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT lihuiping updateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT coussyflorence updateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT callensceline updateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress
AT lereboursflorence updateonbiomarkersofpotentialbenefitwithbevacizumabforbreastcancertreatmentdowemakeprogress